Margaret A. Tempero, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Margaret A. Tempero, MD

Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program; Professor of Medicine, Division of Hematology and Oncology, UCSF
Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science

Phone: (415) 353-9888 (appts)
Box 3211, UCSF
San Francisco, CA 94143-3211

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

I am Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program. My research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. I was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. My group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials, and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. I directed the first GI SPORE devoted to pancreatic cancer when I was on the faculty of the University of Nebraska and subsequently led the NCI-funded U54 Molecular Target Assessment Team at UCSF. I also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. I have served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. I also serve as co-chair on the Pancreas Task Force Tissue Acquisition Working Group for the NCI intergroup and co-organized the State of the Science meeting on pancreatic cancer at the NCI.

I have extensive experience in scientific review and administration, training and oversight. I co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for three years and spent nine years of service teaching this course and similar courses in Europe and Australia. I was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (two-year term) of the NCI Board of Scientific Counselors Subcommittee A. I am on the External Advisory Boards of the Pancreas SPORE at the University of Alabama in Birmingham/University of Minnesota and the Mayo Clinic.

I am, or have been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. I have held many appointments at AACR and ASCO and served as a member of the ASCO Board of Directors and as ASCO President in 2004. I served as a member of the Oncology Drug Advisory Committee for the FDA from 2007-2011. I served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, and Chief of the Division of Medical Oncology at UCSF (2000-2007) and Deputy Director and Director of Research Programs at the HDFCCC from 2000 to 2012.

Education

Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology


Professional Experience

  • 1983-1987
    Asst. Prof. of Med., Dept. of Internal Medicine, University of Nebraska Medical Center (UNMC), Omaha, NE
  • 1987-1994
    Associate Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1985
    Assistant Professor (Courtesy), Eppley Institute for Cancer Research, Omaha, NE
  • 1994-1999
    Professor of Medicine, Dept of Internal Medicine, UNMC, Omaha, NE
  • 1983-1999
    Chief of Oncology/Hematology, V.A. Medical Center, Omaha, NE
  • 1997-1999
    Interim Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1995-1999
    Deputy Director, UNMC/Eppley Cancer Center, Omaha, NE
  • 1998-2003
    Member, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 1999-present
    Member, Scientific Advisory Board, Pancreatic Cancer Action Network (PanCAN)
  • 2000- 2007
    Chief of Medical Oncology, UCSF School of Medicine
  • 2000- 2012
    Deputy Director, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2000-present
    Professor of Medicine, UCSF School of Medicine
  • 2003-2004
    President, Board of Directors, American Society of Clinical Oncology (ASCO)
  • 2004-present
    Member, Scientific Advisory Board, V Foundation
  • 2012-present
    Member, Mayo Clinic Annual SPORE Scientific Retreat
  • 2012-present
    Director, UCSF Pancreas Center
  • 2012-present
    Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
  • 2013-present
    Member, External Advisory Board, University of Alabama at Birmingham/University of Minnesota Pancreatic SPORE

Selected Publications

  1. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA. Hypermutation In Pancreatic Cancer. Gastroenterology. 2016 Nov 15.
    View on PubMed
  2. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400.
    View on PubMed
  3. Maitra A, Fernández-Del Castillo C, Pandol SJ, Saluja AK, Conwell DL, Sahin-Tóth M, Tempero MA, Go VL. Minutes of the Business Meeting of the American Pancreatic Association, Friday, November 6, 2015, San Diego, California. Pancreas. 2016 Nov; 45(10):1376-1377.
    View on PubMed
  4. Tempero M. My Knee Hurts! J Natl Compr Canc Netw. 2016 Nov; 14(11):1335.
    View on PubMed
  5. Tempero M. Crossing the Line. J Natl Compr Canc Netw. 2016 Oct; 14(10):1191.
    View on PubMed
  6. Tempero M. Hillary and Donald, Our Patients Are Watching. J Natl Compr Canc Netw. 2016 Sep; 14(9):1047.
    View on PubMed
  7. Tempero M. I'll Have Another Shot, Please! J Natl Compr Canc Netw. 2016 Aug; 14(8):929.
    View on PubMed
  8. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596.
    View on PubMed
  9. Tempero M. The Greatest Show on Earth! J Natl Compr Canc Netw. 2016 Jul; 14(7):813.
    View on PubMed
  10. Tempero M. Did the IRB Approve This? J Natl Compr Canc Netw. 2016 Jun; 14(6):699.
    View on PubMed
  11. Tempero M. Closely Guarded Secrets. J Natl Compr Canc Netw. 2016 May; 14(5):487.
    View on PubMed
  12. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016; 2:16022.
    View on PubMed
  13. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Apr; 45(3):370-5.
    View on PubMed
  14. Tempero M. Letting Nature Loose. J Natl Compr Canc Netw. 2016 Apr; 14(4):367.
    View on PubMed
  15. Tempero M. Promising the Moon! J Natl Compr Canc Netw. 2016 Mar; 14(3):237.
    View on PubMed
  16. Tempero M. Put Us Out of Business-Please! J Natl Compr Canc Netw. 2016 Feb; 14(2):123.
    View on PubMed
  17. Tempero M. Bringing Biosimilars to the Clinic: What's the Fuss? J Natl Compr Canc Netw. 2016 Jan; 14(1):1.
    View on PubMed
  18. Tempero M. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. J Oncol Pract. 2016 Jan; 12(1):29-30.
    View on PubMed
  19. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2016 Mar; 6(3):270-85.
    View on PubMed
  20. Tempero M. Paying Less for High-Value Care-Are You Kidding Me? J Natl Compr Canc Netw. 2015 Dec; 13(12):1453.
    View on PubMed

Go to UCSF Profiles, powered by CTSI